Nanoformulation of a novel potent ebselen analog for treatment of vulvovaginal candidiasis.
Nanomedicine (Lond)
; 18(18): 1195-1206, 2023 08.
Article
en En
| MEDLINE
| ID: mdl-37724540
ABSTRACT
Background:
Vulvovaginal candidiasis is primarily caused by Candida albicans (C. albicans). Here, a novel organoselenium compound (G20) was synthesized and evaluated for anti-Candida activity.Methods:
Growth-inhibition studies and medium acidification assays to assess the inhibition of the yeast plasma membrane H+-ATPase (Pma1p) were carried out in vitro using G20. A self-nanoemulsifying formulation (SNEP) of G20 was prepared and evaluated for antimycotic activity in a mouse model.Results:
G20 inhibited the growth of C. albicans through a mechanism that, at least in part, involves the inhibition of Pma1p. The G20-SNEP formulation significantly reduced vaginal colonization and vaginal inflammation relative to yeast-infected but untreated control mice.Conclusion:
G20-SNEP exhibits potent antimycotic activity in a mouse model of vulvovaginal candidiasis.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Candidiasis Vulvovaginal
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos